Q-omics provides the consensus-scored RAB8A profile across patient tissues and cancer cell-line models. RAB8A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, RAB8A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RAB8A protein abundance shows 20,499 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SCLC, HNSC, and PDAC as cancer lineages where RAB8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB8A survival associations across molecular data types. RAB8A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB8A RNA expression–survival associations across cancer types. High RAB8A expression shows unfavorable associations in ACC, UVM, LGG and PAAD, but favorable associations in SCLC and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for RAB8A RNA expression.
This table summarizes RAB8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB8A shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, BLCA, STAD and BRCA. The HNSC box plot shows higher RAB8A RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with RAB8A in patient tissues and cancer cell lines. In patient samples, RAB8A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
